Metal-Binding CYP11B2 Inhibitors for Aldosterone-Cortisol Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for aldosterone-related diseases, such as hypertension and fibrosis, face challenges due to the lack of selective inhibitors for CYP11B2, the enzyme responsible for aldosterone biosynthesis, leading to potential off-target effects and clinical toxicity.
Innovation Solution
Development of specific metalloenzyme inhibitors, particularly targeting CYP11B2, with optimized metal-binding groups to balance potency and selectivity, reducing the risk of off-target enzyme inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nonselective MR antagonists like spironolactone are used to block aldosterone effects, then morbidity and mortality are reduced, but off-target effects including gynaecomastia and hyperkalemia occur
Solution Approach 1:
The invention segments the therapeutic effect by developing compounds that selectively inhibit CYP11B2 (aldosterone synthase) while sparing CYP11B1 (11β-hydroxylase). This enzymatic segmentation allows blockade of aldosterone production without affecting cortisol synthesis, thereby achieving antihypertensive benefits while avoiding the off-target effects associated with nonselective MR antagonists.
Solution Approach 2:
The invention introduces CYP11B2 inhibition as an intermediary mechanism to achieve the desired therapeutic effect. Instead of directly blocking MR receptors (which causes off-target effects), the compounds act upstream by inhibiting aldosterone synthesis via CYP11B2, thereby mediating the therapeutic effect without the harmful downstream consequences of receptor antagonism.
2Power
If CYP11B2 inhibition is achieved with high potency, then aldosterone production is effectively blocked, but selectivity against CYP11B1 may be compromised leading to cortisol suppression
Solution Approach 1:
The invention applies local quality by designing metal-binding groups with specific spatial and electronic characteristics that match the unique geometry of the CYP11B2 active site. The compounds feature tailored metal-chelating moieties (such as hydroxamates or carboxylic acids) positioned to interact with the heme iron in CYP11B2, creating a localized interaction that exploits subtle differences in the enzyme's active site architecture to achieve both potency and selectivity.
Solution Approach 2:
The invention utilizes parameter changes by modifying the chemical structure of metal-binding groups to optimize the balance between potency and selectivity. By adjusting parameters such as the pKa of the metal-chelating group, the steric bulk of substituents, and the electronic properties of the metal-binding moiety, the compounds achieve enhanced binding affinity for CYP11B2 while maintaining discrimination against CYP11B1.
3Quantity of substance
If MR antagonism is used to treat aldosterone-related diseases, then fluid retention is reduced, but renin and aldosterone levels elevate exacerbating MR-independent effects
Solution Approach 1:
The invention applies preliminary action by blocking aldosterone synthesis before it can exert any effects, either MR-dependent or MR-independent. By inhibiting CYP11B2 upstream in the biosynthetic pathway, the compounds prevent aldosterone formation entirely, thereby eliminating both the classic volume-retaining effects and the harmful MR-independent effects that occur with MR antagonism where aldosterone levels remain elevated.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These inhibitors effectively block aldosterone production without affecting cortisol synthesis, offering a safer and more targeted treatment for aldosterone-related diseases.
Implementation Method 1
CYP11B2 is a mitochondrial cytochrome P450 enzyme which converts 11-deoxycorticosterone to aldosterone
Implementation Method 2
The highly homologous metalloenzyme CYP11B1 (11-β-steroid-hydroxylase) catalyzes the formation of the primary glucocorticoid cortisol from 11-deoxycortisol
Implementation Method 3
One of the most important functions of metals such as zinc and iron in biological systems is to enable the activity of metalloenzymes. Metalloenzymes are enzymes that incorporate metal ions into the enzyme active site and utilize the metal as a part of the catalytic process
Data Source
AI summary
Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.